SUNLENCA® Demonstrated Rapid and Long-acting Antiviral Activity1
88% of participants taking SUNLENCA achieved a ≥0.5 log10 copies/mL reduction in HIV-1 RNA after 14 days vs 17% of participants taking placebo1,*
Primary Endpoint: Proportion of Participants Achieving a ≥0.5 log10 Decrease in Viral Load (Randomized Cohort) at Day 151,2
*In the randomized cohort (n=36).
Important Safety Information
Adverse reactions
- Most common adverse reactions (incidence ≥3%, all grades) are injection site reactions (65%) and nausea (4%).
After 1 SC dose, 81% of participants taking SUNLENCA achieved virologic suppression at Week 26, and 83% of participants achieved virologic suppression at Week 521,†,‡
Secondary Endpoints: Weeks 26 and 52
View More Efficacy Data
Virologic Outcomes With SUNLENCA + Optimized Background Regimen
(Randomized Cohort)1,§
Virologic Outcomes (HIV-1 RNA <50 copies/mL) at Week 52 With
SUNLENCA + Optimized Background Regimen (Randomized Cohort)3,§
†In the randomized cohort (n=36).
‡In CAPELLA across cohorts 1 and 2, 79% of participants (57/72) received SUNLENCA 300 mg once every 7 days as oral bridging at some point during the 52-week treatment period.
86% of PARTICIPANTS were able to achieve HIV-1 RNA <200 copies/mL at Week 52 in the randomized cohort with SUNLENCA + OBR4
Click for Important Safety Information for SUNLENCA.
More participants whose OBR included ≥1 fully active ARV achieved virologic suppression at Week 52 when compared to those without any fully active agents1
- ≥2 fully active ARVs: 94% (n=15/16)
- 1 fully active ARV: 79% (n=11/14)
- No fully active ARV: 67% (n=4/6)
Virologic suppression (HIV-1 RNA <50/mL) with SUNLENCA by number of fully active agents in OBR:
ACHIEVING RAPID AND SUSTAINED SUPPRESSION is POSSIBLE with SUNLENCA1